Anna Aagaard

BioPharmaceuticals R&D, AstraZeneca
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Mineralocorticoid Receptor Antagonists With an Acylurea as a Key Polar Interaction Motif.

Mineralocorticoid Receptor Antagonists With an Acylurea as a Key Polar Interaction Motif.

Journal: ChemMedChem

Published: November 19, 2025

Discovery and Validation of a Novel Class of Necroptosis Inhibitors Targeting RIPK1.

Discovery and Validation of a Novel Class of Necroptosis Inhibitors Targeting RIPK1.

Journal: ACS chemical biology

Published: June 20, 2025

Generation of a potent & selective series of IRAK4 inhibitors based on a structure based, hybridization approach.

Generation of a potent & selective series of IRAK4 inhibitors based on a structure based, hybridization approach.

Journal: Bioorganic & medicinal chemistry

Published: June 11, 2025

Thermostable ancestors enabled evolutionary diversification of promiscuous chemical defence enzymes.

Thermostable ancestors enabled evolutionary diversification of promiscuous chemical defence enzymes.

Journal: The EMBO journal

Published: February 06, 2025

Identification and optimisation of a pyrimidopyridone series of IRAK4 inhibitors.

Identification and optimisation of a pyrimidopyridone series of IRAK4 inhibitors.

Journal: Bioorganic & medicinal chemistry

Published: January 13, 2022

AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2.

AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2.

Journal: Journal of medicinal chemistry

Published: August 31, 2021

Fragment-Based Discovery of Novel Allosteric MEK1 Binders.

Fragment-Based Discovery of Novel Allosteric MEK1 Binders.

Journal: ACS medicinal chemistry letters

Published: October 20, 2020

Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors.

Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors.

Journal: Bioorganic & medicinal chemistry

Published: September 01, 2020

Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2.

Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2.

Journal: ACS medicinal chemistry letters

Published: April 05, 2019

Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection.

Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection.

Journal: Journal of medicinal chemistry

Published: January 01, 2019

Molecular tuning of farnesoid X receptor partial agonism.

Molecular tuning of farnesoid X receptor partial agonism.

Journal: Nature communications

Published: October 18, 2018

Potent and Orally Bioavailable Inverse Agonists of RORγt Resulting from Structure-Based Design.

Potent and Orally Bioavailable Inverse Agonists of RORγt Resulting from Structure-Based Design.

Journal: Journal of medicinal chemistry

Published: August 11, 2018

Showing 1-12 of 20

Last Updated: 09/26/2026